Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a novel combination treatment using MDMA and N-Acylethanolamines. This innovative approach aims to enhance safety and efficacy in mental health and addiction treatments. The patent is part of Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on integrating psychedelic molecules with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that this combination therapy addresses FDA safety concerns about MDMA by potentially reducing its dosage while maintaining therapeutic efficacy. The company has filed thirteen patents related to this collaboration in various global jurisdictions, demonstrating their commitment to developing innovative treatments for mental health disorders and addictions.
Clearmind Medicine Inc. (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto internazionale per un nuovo trattamento combinato che utilizza MDMA e N-Acylethanolamines. Questo approccio innovativo mira a migliorare la sicurezza e l'efficacia nei trattamenti per la salute mentale e le dipendenze. Il brevetto fa parte della collaborazione di Clearmind con SciSparc (Nasdaq: SPRC), focalizzandosi sull'integrazione delle molecole psichedeliche con gli N-Acylethanolamines, tra cui il Palmitoiletanolamide (PEA).
Il dott. Adi Zuloff-Shani, CEO di Clearmind, ha sottolineato che questa terapia combinata affronta le preoccupazioni di sicurezza della FDA riguardo all'MDMA, riducendo potenzialmente il suo dosaggio mantenendo l'efficacia terapeutica. L'azienda ha presentato tredici brevetti correlati a questa collaborazione in varie giurisdizioni globali, dimostrando il suo impegno nello sviluppo di trattamenti innovativi per i disturbi mentali e le dipendenze.
Clearmind Medicine Inc. (Nasdaq: CMND) ha anunciado la publicación de una solicitud de patente internacional para un nuevo tratamiento combinado que utiliza MDMA y N-Acylethanolamines. Este enfoque innovador tiene como objetivo mejorar la seguridad y la eficacia en los tratamientos de salud mental y adicciones. La patente es parte de la colaboración de Clearmind con SciSparc (Nasdaq: SPRC), enfocándose en integrar moléculas psicodélicas con N-Acylethanolamines, incluyendo el Palmitoiletanolamida (PEA).
El Dr. Adi Zuloff-Shani, CEO de Clearmind, enfatizó que esta terapia combinada aborda las preocupaciones de seguridad de la FDA sobre el MDMA al reducir potencialmente su dosis mientras mantiene la eficacia terapéutica. La empresa ha presentado trece patentes relacionadas con esta colaboración en diversas jurisdicciones globales, demostrando su compromiso en desarrollar tratamientos innovadores para trastornos mentales y adicciones.
클리어마인드 메디신 주식회사 (Nasdaq: CMND)는 MDMA 및 N-아실에탄올아민을 사용하는 새로운 조합 치료법에 대한 국제 특허 출원을 발표했습니다. 이 혁신적인 접근 방식은 정신 건강 및 중독 치료의 안전성과 효능을 향상시키는 것을 목표로 합니다. 이 특허는 Psychedelic 분자를 Palmitoylethanolamide (PEA)를 포함한 N-아실에탄올아민과 통합하는 데 중점을 둔 Clearmind와 SciSparc (Nasdaq: SPRC)의 협력의 일환입니다.
Clearmind의 CEO인 Adi Zuloff-Shani 박사는 이 조합 치료법이 MDMA에 대한 FDA의 안전성 우려를 다룬다고 강조했으며, 치료적 효능을 유지하면서 잠재적으로 용량을 줄일 수 있다고 설명했습니다. 이 회사는 정신 건강 장애 및 중독을 위한 혁신적인 치료법 개발에 대한 약속을 보여주는 다양한 글로벌 관할권에 걸쳐 이 협력과 관련된 13개의 특허를 제출했습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a annoncé la publication d'une demande de brevet international pour un nouveau traitement combiné utilisant MDMA et N-Acylethanolamines. Cette approche innovante vise à améliorer la sécurité et l'efficacité dans les traitements de santé mentale et de dépendance. Le brevet fait partie de la collaboration de Clearmind avec SciSparc (Nasdaq: SPRC), axée sur l'intégration des molécules psychédéliques avec les N-Acylethanolamines, y compris le Palmitoïléthanolamide (PEA).
Le Dr Adi Zuloff-Shani, PDG de Clearmind, a souligné que cette thérapie combinée répond aux préoccupations de sécurité de la FDA concernant l'MDMA, en réduisant potentiellement sa posologie tout en maintenant l'efficacité thérapeutique. L'entreprise a déposé treize brevets liés à cette collaboration dans différentes juridictions mondiales, démontrant son engagement à développer des traitements innovants pour les troubles mentaux et les addictions.
Clearmind Medicine Inc. (Nasdaq: CMND) hat die Veröffentlichung eines internationalen Patentantrags für eine neuartige Kombinationstherapie mit MDMA und N-Acylethanolaminen angekündigt. Dieser innovative Ansatz zielt darauf ab, Sicherheit und Wirksamkeit bei der Behandlung von psychischen Erkrankungen und Suchterkrankungen zu verbessern. Das Patent ist Teil der Zusammenarbeit von Clearmind mit SciSparc (Nasdaq: SPRC), die sich auf die Integration psychedelischer Moleküle mit N-Acylethanolaminen, einschließlich Palmitoylethanolamid (PEA), konzentriert.
Dr. Adi Zuloff-Shani, CEO von Clearmind, betonte, dass diese Kombinationstherapie die Sicherheitsbedenken der FDA bezüglich MDMA anspricht, indem sie möglicherweise die Dosis reduziert und gleichzeitig die therapeutische Wirksamkeit aufrechterhält. Das Unternehmen hat dreizehn Patente im Zusammenhang mit dieser Zusammenarbeit in verschiedenen globalen Jurisdiktionen eingereicht, was ihr Engagement für die Entwicklung innovativer Behandlungen für psychische Erkrankungen und Süchte zeigt.
- Publication of international patent application for MDMA-based combination treatment
- Collaboration with SciSparc on innovative therapies
- Thirteen patents filed in multiple global jurisdictions
- Potential to address FDA safety concerns regarding MDMA
- None.
Insights
The publication of Clearmind Medicine's international patent application for an MDMA-based combination treatment is a significant development in the psychedelic therapeutics field. This innovative approach, combining MDMA with N-Acylethanolamines like PEA, aims to address a important challenge in MDMA therapy: dose-related toxicity. By potentially reducing the required MDMA dosage, this combination could mitigate safety concerns while maintaining therapeutic efficacy.
The collaboration with SciSparc, resulting in 13 patent filings across multiple jurisdictions, demonstrates a robust R&D pipeline. This strategic move could position Clearmind favorably in the competitive landscape of psychedelic-derived therapeutics. However, it's important to note that patent applications don't guarantee approval or market success. The true value of this approach will depend on future clinical trial results and regulatory approvals.
While this patent application is a positive step for Clearmind Medicine (NASDAQ: CMND), investors should approach with cautious optimism. The psychedelic therapeutics market is projected to grow significantly, potentially reaching
The company's strategy of combining MDMA with PEA could provide a competitive edge if successful, potentially addressing a
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy
in Mental Health and Addiction Treatments
Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.
The patent application was filed as part of the Company's ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty pharmaceutical company in the clinical trial phase, dedicated to developing treatments for central nervous system disorders.
Under this collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented on the announcement: “The continued evolution of our patent portfolio reflects our strategic commitment to bringing innovative and effective treatments to market. While MDMA has shown promising clinical benefits as a standalone therapy, it also presents potential dose-limiting toxicities. Our unique combination of MDMA and PEA is designed to address critical safety concerns raised by the FDA regarding MDMA's safety profile. By combining MDMA with PEA, we aim to significantly reduce the MDMA dosage, thereby minimizing potential risks while maintaining therapeutic efficacy. We believe our strategy of combining psychedelic molecules and N-Acylethanolamines, could pave the way for a new era in the treatment of mental health disorders and addictions."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how its patent portfolio signifies that its strategy and commitment to bring innovative treatments that are both effective and safe is proving itself and paving the way for a new era in the treatment of mental health disorders and addictions. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new patent application announced by Clearmind Medicine (CMND)?
How does Clearmind's (CMND) MDMA-based treatment aim to improve safety?
Who is Clearmind Medicine (CMND) collaborating with on this patent?
How many patents has Clearmind Medicine (CMND) filed related to this collaboration?
